{
  "source": "PA-Notification-Lytgobi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1399-3\nProgram Prior Authorization/Notification\nMedication Lytgobi® (futibatinib)\nP&T Approval Date 11/2022, 11/2023, 11/2024\nEffective Date 2/15/2025\n1. Background:\nLytgobi (futibatinib) is a kinase inhibitor indicated for the treatment of adult patients with\npreviously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma\nharboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.\nThe National Cancer Comprehensive Network (NCCN) also recommends the use of Lytgobi in\nextrahepatic cholangiocarcinoma for subsequent treatment for progression on or after systemic\ntreatment for unresectable or resected gross residual (R2) disease, or metastatic disease with\nfibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements.\nThis indication is approved under accelerated approval based on overall response rate and duration\nof response. Continued approval for this indication may be contingent upon verification and\ndescription of clinical benefit in a confirmatory trial(s).\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the notification\ncriteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Lytgobi will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Cholangiocarcinoma\n1. Initial Authorization\na. Lytgobi will be approved based on all of the following criteria:\n(1) Diagnosis of cholangiocarcinoma (intrahepatic or extrahepatic)\n©",
    "d for 12 months.\nB. Cholangiocarcinoma\n1. Initial Authorization\na. Lytgobi will be approved based on all of the following criteria:\n(1) Diagnosis of cholangiocarcinoma (intrahepatic or extrahepatic)\n© 2024 UnitedHealthcare Services, Inc.\n1\n-AND-\n(2) Disease is one of the following:\ni. Unresectable\nii. Resected gross residual (R2)\niii. Metastatic\n-AND-\n(3) Positive for fibroblast growth factor receptor 2 (FGFR2) fusions or\nrearrangements\n-AND-\n(4) Used as second line or subsequent treatment\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Lytgobi will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Lytgobi therapy\nAuthorization will be issued for 12 months.\nC. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits and/or step therapy may be in place.\n© 2024 UnitedHealthcare Services, Inc.\n2\n4. References:\n1. Lytgobi [package insert]. Princeton, NJ: Taiho Pharmaceutical Co., Ltd. April 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org. Accessed September 21, 2024.\nProgram Prior Authorization/Notification – Lytgobi® (futibatinib)\nChange Control\n11/2022 New program.\n11/2023 Annual review. ",
    "mpendium™). Available at\nhttp://www.nccn.org. Accessed September 21, 2024.\nProgram Prior Authorization/Notification – Lytgobi® (futibatinib)\nChange Control\n11/2022 New program.\n11/2023 Annual review. Updated cholangiocarcinoma criteria to include NCCN\nrecommendations. Updated background. Added reference.\n11/2024 Annual review. Modified criteria for disease type in\ncholangiocarcinoma. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}